Formulation, Optimization and Evaluation of Eudragit RL 100 nanoparticles loaded with Quercetin for its Hypolipidemic action by using Animal Model

Abstract

Quercetin, a potent pharmacological active phytocompound, plays a crucial role in drug therapy. However, its essential role is limited due to poor water solubility and low bioavailability. To overcome these limitations and enhance oral bioavailability, Quercetin loaded Eudragit nanoparticles were prepared using a single emulsification solvent evaporation method and optimized by applying Box-Behnken design. This study aimed to investigate the anti-hyperlipidemic potential of Quercetin in Triton WR-1339 induced hyperlipidemic rats. Hyperlipidemia was induced in rats using Triton WR-1339, and the hypolipidemic potential of Quercetin was evaluated at doses of 50 and 100 mg/kg. The results revealed that Quercetin significantly (p ≤ 0.005) altered the serum levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol, bringing them close to normal levels in Triton WR-1339 induced hyperlipidemic rats. Furthermore, both doses of Quercetin (50 and 100 mg/kg) showed significant reductions in TC and TG levels when compared to the standard atorvastatin treatment. The novel formulation of Quercetin loaded Eudragit polymeric nanoparticles displayed remarkable potential as a green antihyperlipidemic agent. These findings suggest that Quercetin loaded Eudragit nanoparticles can effectively mitigate hyperlipidemia and have the potential to be a promising therapeutic option for lipid disorders. The enhanced bioavailability and bioactivity of Quercetin delivered through this novel formulation open new possibilities for its clinical application in managing hyperlipidemia. Further research and clinical studies are warranted to explore its translational potential and wider applications in drug therap